FDA approves Folotyn for peripheral T-cell lymphomas

FDA regulators have apparently given accelerated approval to Allos Therapeutics' treatment for peripheral T-cell lymphomas (PTCL), Folotyn (pralatrexate injection) for treatment of relapsed or refractory PTCLs. The drug could be available in the US as soon as October.

Folotyn becomes the first drug FDA-approved to treat PTCLs.

FDA approval comes despite a lack of convincing clinical data that the drug is effective at stopping the spread of PTCL, or that it can even extend survival. At most, Allos has shown in clinical trials that Folotyn can, among some patients, reduce tumor size.

This news shouldn't be greeted by PTCL patients or their caregivers with too much enthusiasm, since the jury should still be considered out on this drug.

Dive Deeper

ClinicalTrials.gov information concerning pralatrexate
Allos press release
Forbes story on FDA approval

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap